Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade - Test2 - elhamkhani - TriplyDB

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade

http://www.wikidata.org/entity/Q34645401

about

Trial Watch Interactions between Autophagy and Inhibitory Cytokines Interleukin-35: Expanding Its Job Profile Once a Treg, always a Treg?Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.HY immune tolerance is common in women without male offspring.Targeting the tumor microenvironment to enhance antitumor immune responses IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects Effect of Regulatory T Cells on Promoting Apoptosis of T Lymphocyte and Its Regulatory Mechanism in Sepsis.Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma Interleukin-35 Limits Anti-Tumor Immunity.Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.Thymic versus induced regulatory T cells - who regulates the regulators?Patterns of Immune Regulation in Rhesus Macaque and Human Families Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade.Assessing the role of IL-35 in colorectal cancer progression and prognosis.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.Monitoring regulatory immune responses in tumor immunotherapy clinical trials.Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance.IL-35: a potential therapeutic target for controlling hepatitis B virus infection.IL-35 and Autoimmunity: a Comprehensive Perspective.Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy.Targeting regulatory T cells in tumors.The Immunobiology of Interleukin-35 and Its Regulation and Gene Expression.[Current Research of the Roles of IL-35 in Tumor Progression].Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.Interleukin-35 on B cell and T cell induction and regulation.Trans-vivo delayed type hypersensitivity assay for antigen specific regulation.Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.Tregs: Where We Are and What Comes Next?Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells.Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection.Human CD8+CD28− T Suppressor Cells Expanded by IL-15 In Vitro Suppress in an Allospecific and Programmed Cell Death Protein 1-Dependent Manner.Description of CD8 Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer

P2860

Q24618653-B47775EB-B51C-4435-9C39-ACCD2937F962 Q26745577-FD1C6C48-7C87-4843-AB56-F89A81247003 Q26829619-F9BCE5F3-0159-4228-BF38-E7D4FA3D2FDD Q33561651-F761C4B1-E376-4A3D-816B-3D9900827765 Q34250904-A9D3CDFD-3904-4A82-B3E5-C686E04DF17A Q35079792-20629A93-C3CD-40E3-A233-D6C16A843459 Q35124977-F0482F2C-BEB3-4C45-8713-754F9C9ADC4B Q35176307-A683EA39-E0A6-471E-BF80-CF51C7FB359D Q35348407-6154FEAA-AB48-4B4E-A252-E45554125AD9 Q36382816-A382F3A8-8AC3-47F1-9FC1-AC820AD2F4AA Q36412024-BDF1102B-266D-420A-AC28-1E51C6597590 Q36593479-5FFF054B-C4B5-4281-B185-12A7B388524B Q36806906-F411D2D9-8842-487D-8231-69BA414F38FB Q36841195-A6A2A529-454A-49C0-9326-1257C5F3E91A Q36959215-E9939A65-64DA-47EB-AF55-0D5D297EC52B Q37097734-0C6EC7A2-AA6D-4F7D-8B65-ED143B27B6FE Q37097813-1AB65508-D9B3-44A8-A6B4-11F55F63EA37 Q37137999-216D04B8-A55F-42C3-B31A-63B3F8960FB1 Q37703163-58558A42-7907-417E-A603-D7CC4CCD1760 Q38105081-573D6ABD-364F-4691-A2FE-F99CCCE17BBA Q38154886-C09C99C3-5516-4D09-8756-825DA9F0BB22 Q38283391-EE2D9F8E-28AD-4F3D-AE4D-7612F8523F6B Q38331780-774266AB-D1F3-46A6-8099-A763B5D6C646 Q38650594-2497D4F4-35A1-40E2-A410-B4985FB65476 Q38703565-C7493667-CF83-4DB0-BDED-2B3B840E9FB6 Q40508635-0CD77EA1-BD1C-49E9-B1A9-A245222453A4 Q40779943-E456CFC5-7A37-482F-8485-84F256EC9C7C Q41041538-BCB9BCA4-A0CE-4861-84D0-2998471A86B7 Q41292130-F95A5D5B-EC93-4839-89CC-569BAE25EBCA Q41428670-8199B013-1B49-4463-93FE-17903009BF7D Q41869616-7E786064-0572-4DEB-8C89-9BF709477F46 Q47105622-092B452B-E65D-454C-B554-2DBAC67CCE45 Q47141380-A416DC37-6DE7-4F04-8EA5-7CB3A6C25638 Q51641181-1725E9B4-247C-4847-89AE-04D20068181A Q54217573-7771A8CA-16EC-400A-A95D-D0EC13819D78 Q55514835-8BF074FF-EDDE-42A9-9D3D-181649229BFB Q56890349-9F642EDB-7B2D-468C-9EDC-1F7B3BF11244

P2860

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade

http://www.wikidata.org/entity/Q34645401

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@ast

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@en

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@nl

type

label

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@ast

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@en

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@nl

prefLabel

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@ast

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@en

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@nl

P1433

Q34645401-A55F7612-CDAF-408C-BA3E-F8401F92B7D9

P1476

Q34645401-8F982517-602D-4FF4-8DEC-7A8B34D48E32

P2093

Q34645401-42065CFA-05E1-4BD0-846A-C4DDB3BD62B2

Q34645401-4C2D9B95-8308-4B5B-B5C6-2334CF5DE3E7

Q34645401-6DB16061-EF6A-4F3D-91F3-D6FA62A90C55

Q34645401-7C66C8F2-4428-48EA-A9B5-1542355F6044

Q34645401-858BD354-8606-4A84-BC52-AF82CB48E5AB

Q34645401-E79123D5-3B52-4547-A699-01F4B5948667

P2860

Q34645401-06E4EEDE-22CF-4945-B72B-42E30F07D15B

Q34645401-0A724D14-B550-460B-A361-38836C8F6C10

Q34645401-0AA9CD27-B987-427F-A0E7-FD037F1792C3

Q34645401-0B4EBB70-71EF-467B-A71C-819D52CB3350

Q34645401-0F85F808-F5C1-4F47-A2E1-45A56971654C

Q34645401-13203809-AF0B-481D-87F4-CB021C32C99F

Q34645401-160AF8C8-FF7B-4D1B-A2E0-6BF8DD4373B4

Q34645401-28677F57-8E20-4BBB-B0AD-847A7B346D36

Q34645401-2F6D57C6-4170-4668-BBF0-BDA289FD7B88

Q34645401-4488FF90-411F-40BF-B7A5-9A37D664E9F4

P304

Q34645401-4F276F2F-7CD3-408B-B902-E07935E8585B

P31

Q34645401-3C760704-18B4-456A-A07E-1F346D230F34

P356

Q34645401-0872EEAB-E877-4B73-B477-BB3875F8422E

P407

Q34645401-CF0F3EAF-AFA1-4844-A28A-4C9E5A59728E

P433

Q34645401-2CD07B8B-D1EF-4C18-A0D6-4E99F698B9A2

P478

Q34645401-DECC9EF2-808D-44E3-BFF7-E4852B16D4FC

P577

Q34645401-E6F2853D-4E0E-491F-BB9C-67573376CFA3

P698

Q34645401-E9E9DE4C-5002-492F-8174-160F8857261A

P932

Q34645401-F6ACBBD8-AAC4-4D19-B7CE-5F00E49B848A

P356

JIMMUNOL.1201744

P1433

Journal of Immunology

P1476

Human prostate tumor antigen-s ...... ed by CTLA-4 or IL-35 blockade

@en

P2093

Brian M Olson

http://www.w3.org/2001/XMLSchema#string

Dario A A Vignali

http://www.w3.org/2001/XMLSchema#string

Douglas G McNeel

http://www.w3.org/2001/XMLSchema#string

Ewa Jankowska-Gan

http://www.w3.org/2001/XMLSchema#string

Jordan T Becker

http://www.w3.org/2001/XMLSchema#string

William J Burlingham

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

A new mathematical model for relative quantification in real-time RT-PCR

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.

Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells.

IL-35-mediated induction of a potent regulatory T cell population.

Type 1 T regulatory cells.

P304

5590-5601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1201744

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23152566

http://www.w3.org/2001/XMLSchema#string

P932

3735346

http://www.w3.org/2001/XMLSchema#string